Korean J Gastroenterol.  2021 Feb;77(2):77-83. 10.4166/kjg.2021.025.

Endoscopic Management of Dysphagia

• Kim MJ
• Min YW

• KMID: 2513417
• DOI: http://doi.org/10.4166/kjg.2021.025

Abstract

Dysphagia is difficulty in swallowing that can be caused by a number of disorders that involve either the oropharynx or the esophagus. Specific endoscopic treatment for dysphagia depends on its etiology, whether the dysphagia is caused by mechanical narrowing or a motor disorder. Variable endoscopic treatment strategies can be used to manage dysphagia. Patient with dysfunction of the upper esophageal sphincter may benefit from esophageal dilationor injection of botulinum toxin. Pneumatic balloon dilation, injection of botulinum toxin, peroral endoscopic myotomy can be considered as treatment options for esophageal motility disorders. Endoscopic dilation is the treatment choice of esophageal stricture, while intraluminal steroid injection and temporary stent can be considered in refractory benign esophageal stricture. Self-expandable metal stent insertion can be considered for dysphagia with malignant cause.

Keyword

Deglutition disorders; Endoscopy

Reference

1. Abdel Jalil AA, Katzka DA, Castell DO. 2015; Approach to the patient with dysphagia. Am J Med. 128:1138.e17–23. DOI: 10.1016/j.amjmed.2015.04.026. PMID: 26007674.

2. Cook IJ, Kahrilas PJ. 1999; AGA technical review on management of oropharyngeal dysphagia. Gastroenterology. 116:455–478. DOI: 10.1016/S0016-5085(99)70144-7. PMID: 9922328.

3. Ferreira LE, Simmons DT, Baron TH. 2008; Zenker's diverticula: pathophysiology, clinical presentation, and flexible endoscopic management. Dis Esophagus. 21:1–8. DOI: 10.1111/j.1442-2050.2007.00795.x. PMID: 18197932.

4. Rofes L, Arreola V, Almirall J, et al. 2011; Diagnosis and management of oropharyngeal dysphagia and its nutritional and respiratory complications in the elderly. Gastroenterol Res Pract. 2011:818979. DOI: 10.1155/2011/818979. PMID: 20811545. PMCID: PMC2929516.

5. Kelly EA, Koszewski IJ, Jaradeh SS, Merati AL, Blumin JH, Bock JM. 2013; Botulinum toxin injection for the treatment of upper esophageal sphincter dysfunction. Ann Otol Rhinol Laryngol. 122:100–108. DOI: 10.1177/000348941312200205. PMID: 23534124. PMCID: PMC3951150.

6. Ravich WJ. 2001; Botulinum toxin for UES dysfunction: therapy or poison? Dysphagia. 16:168–170. DOI: 10.1007/s00455-001-0060-1. PMID: 11453561.

7. Schneider I, Thumfart WF, Pototschnig C, Eckel HE. 1994; Treatment of dysfunction of the cricopharyngeal muscle with botulinum A toxin: introduction of a new, noninvasive method. Ann Otol Rhinol Laryngol. 103:31–35. DOI: 10.1177/000348949410300105. PMID: 8291857.

8. Solt J, Bajor J, Moizs M, Grexa E, Horváth PO. 2001; Primary cricopharyngeal dysfunction: treatment with balloon catheter dilatation. Gastrointest Endosc. 54:767–771. DOI: 10.1067/mge.2001.118442. PMID: 11726859.

9. Moerman MB. 2006; Cricopharyngeal Botox injection: indications and technique. Curr Opin Otolaryngol Head Neck Surg. 14:431–436. DOI: 10.1097/MOO.0b013e328010b85b. PMID: 17099352.

10. Kuhn MA, Belafsky PC. 2013; Management of cricopharyngeus muscle dysfunction. Otolaryngol Clin North Am. 46:1087–1099. DOI: 10.1016/j.otc.2013.08.006. PMID: 24262961.

11. Chandrasekhara V, Koh J, Lattimer L, Dunbar KB, Ravich WJ, Clarke JO. 2017; Endoscopic balloon catheter dilatation via retrograde or static technique is safe and effective for cricopharyngeal dysfunction. World J Gastrointest Endosc. 9:183–188. DOI: 10.4253/wjge.v9.i4.183. PMID: 28465785. PMCID: PMC5394725.

12. Clary MS, Daniero JJ, Keith SW, Boon MS, Spiegel JR. 2011; Efficacy of large-diameter dilatation in cricopharyngeal dysfunction. Laryngoscope. 121:2521–2525. DOI: 10.1002/lary.22365. PMID: 21997884.

13. Nabi Z, Reddy DN. 2020; Endoscopic management of Zenker's diverticulum. Int J Gastrointest Interv. 9:78–85. DOI: 10.18528/ijgii200004.

14. Johnston BT. 2017; Oesophageal dysphagia: a stepwise approach to diagnosis and management. Lancet Gastroenterol Hepatol. 2:604–609. DOI: 10.1016/S2468-1253(17)30001-8. PMID: 28691686.

15. Kahrilas PJ, Bredenoord AJ, Fox M, et al. 2015; The Chicago Classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil. 27:160–174. DOI: 10.1111/nmo.12477. PMID: 25469569. PMCID: PMC4308501.

16. Rohof WO, Salvador R, Annese V, et al. 2013; Outcomes of treatment for achalasia depend on manometric subtype. Gastroenterology. 144:718–725. DOI: 10.1053/j.gastro.2012.12.027. PMID: 23277105.

17. Pandolfino JE, Gawron AJ. 2015; Achalasia: a systematic review. JAMA. 313:1841–1852. DOI: 10.1001/jama.2015.2996. PMID: 25965233.

18. Boeckxstaens GE, Annese V, des Varannes SB, et al. 2011; Pneumatic dilation versus laparoscopic Heller's myotomy for idiopathic achalasia. N Engl J Med. 364:1807–1816. DOI: 10.1056/NEJMoa1010502. PMID: 21561346.

19. Moonen A, Annese V, Belmans A, et al. 2016; Long-term results of the European achalasia trial: a multicentre randomised controlled trial comparing pneumatic dilation versus laparoscopic Heller myotomy. Gut. 65:732–739. DOI: 10.1136/gutjnl-2015-310602. PMID: 26614104.

20. Sawas T, Ravi K, Geno DM, et al. 2017; The course of achalasia one to four decades after initial treatment. Aliment Pharmacol Ther. 45:553–560. DOI: 10.1111/apt.13888. PMID: 27925255.

21. Ghoshal UC, Rangan M. 2011; A review of factors predicting outcome of pneumatic dilation in patients with achalasia cardia. J Neurogastroenterol Motil. 17:9–13. DOI: 10.5056/jnm.2011.17.1.9. PMID: 21369487. PMCID: PMC3042226.

22. van Hoeij FB, Prins LI, Smout AJPM, Bredenoord AJ. 2019; Efficacy and safety of pneumatic dilation in achalasia: a systematic review and meta-analysis. Neurogastroenterol Motil. 31:e13548. DOI: 10.1111/nmo.13548. PMID: 30697952. PMCID: PMC6849773.

23. Vaezi MF, Pandolfino JE, Vela MF. 2013; ACG clinical guideline: diagnosis and management of achalasia. Am J Gastroenterol. 108:1238–1250. DOI: 10.1038/ajg.2013.196. PMID: 23877351.

24. Vanuytsel T, Lerut T, Coosemans W, et al. 2012; Conservative management of esophageal perforations during pneumatic dilation for idiopathic esophageal achalasia. Clin Gastroenterol Hepatol. 10:142–149. DOI: 10.1016/j.cgh.2011.10.032. PMID: 22064041.

25. Khan MA, Kumbhari V, Ngamruengphong S, et al. 2017; Is POEM the answer for management of spastic esophageal disorders? A systematic review and meta-analysis. Dig Dis Sci. 62:35–44. DOI: 10.1007/s10620-016-4373-1. PMID: 27858325.

26. Kim JY, Min YW. 2020; Peroral endoscopic myotomy for esophageal motility disorders. Clin Endosc. 53:638–645. DOI: 10.5946/ce.2020.223. PMID: 33212547. PMCID: PMC7719430.

27. Li QL, Yao LQ, Xu XY, et al. 2016; Repeat peroral endoscopic myotomy: a salvage option for persistent/recurrent symptoms. Endoscopy. 48:134–140. DOI: 10.1055/s-0034-1393095. PMID: 26349067.

28. Von Renteln D, Fuchs KH, Fockens P, et al. 2013; Peroral endoscopic myotomy for the treatment of achalasia: an international prospective multicenter study. Gastroenterology. 145:309–11.e113. DOI: 10.1053/j.gastro.2013.04.057. PMID: 23665071.

29. Werner YB, Costamagna G, Swanström LL, et al. 2016; Clinical response to peroral endoscopic myotomy in patients with idiopathic achalasia at a minimum follow-up of 2 years. Gut. 65:899–906. DOI: 10.1136/gutjnl-2014-308649. PMID: 25934759.

30. Schlottmann F, Luckett DJ, Fine J, Shaheen NJ, Patti MG. 2018; Laparoscopic Heller myotomy versus peroral endoscopic myotomy (POEM) for achalasia: a systematic review and metaanalysis. Ann Surg. 267:451–460. DOI: 10.1097/SLA.0000000000002311. PMID: 28549006.

31. Chan SM, Wu JC, Teoh AY, et al. 2016; Comparison of early outcomes and quality of life after laparoscopic Heller's cardiomyotomy to peroral endoscopic myotomy for treatment of achalasia. Dig Endosc. 28:27–32. DOI: 10.1111/den.12507. PMID: 26108140.

32. Ponds FA, Fockens P, Lei A, et al. 2019; Effect of peroral endoscopic myotomy vs pneumatic dilation on symptom severity and treatment outcomes among treatment-naive patients with achalasia: a randomized clinical trial. JAMA. 322:134–144. DOI: 10.1001/jama.2019.8859. PMID: 31287522. PMCID: PMC6618792.

33. Ling T, Guo H, Zou X. 2014; Effect of peroral endoscopic myotomy in achalasia patients with failure of prior pneumatic dilation: a prospective case-control study. J Gastroenterol Hepatol. 29:1609–1613. DOI: 10.1111/jgh.12570. PMID: 24628480.

34. Ngamruengphong S, Inoue H, Ujiki MB, et al. 2017; Efficacy and safety of peroral endoscopic myotomy for treatment of achalasia after failed Heller myotomy. Clin Gastroenterol Hepatol. 15:1531–1537.e3. DOI: 10.1016/j.cgh.2017.01.031. PMID: 28189695.

35. Tyberg A, Seewald S, Sharaiha RZ, et al. 2017; A multicenter international registry of redo per-oral endoscopic myotomy (POEM) after failed POEM. Gastrointest Endosc. 85:1208–1211. DOI: 10.1016/j.gie.2016.10.015. PMID: 27756611.

36. Pasricha PJ, Ravich WJ, Hendrix TR, Sostre S, Jones B, Kalloo AN. 1995; Intrasphincteric botulinum toxin for the treatment of achalasia. N Engl J Med. 332:774–778. DOI: 10.1056/NEJM199503233321203. PMID: 7862180.

37. Pasricha PJ, Rai R, Ravich WJ, Hendrix TR, Kalloo AN. 1996; Botulinum toxin for achalasia: long-term outcome and predictors of response. Gastroenterology. 110:1410–1415. DOI: 10.1053/gast.1996.v110.pm8613045. PMID: 8613045.

38. Zaninotto G, Annese V, Costantini M, et al. 2004; Randomized controlled trial of botulinum toxin versus laparoscopic heller myotomy for esophageal achalasia. Ann Surg. 239:364–370. DOI: 10.1097/01.sla.0000114217.52941.c5. PMID: 15075653. PMCID: PMC1356234.

39. Leyden JE, Moss AC, MacMathuna P. 2014; Endoscopic pneumatic dilation versus botulinum toxin injection in the management of primary achalasia. Cochrane Database Syst Rev. (12):CD005046. DOI: 10.1002/14651858.CD005046.pub3. PMID: 25485740.

40. Zaninotto G, Bennett C, Boeckxstaens G, et al. 2018; The 2018 ISDE achalasia guidelines. Dis Esophagus. 31(9):DOI: 10.1093/dote/doy071. PMID: 30169645.

41. Song BG, Min YW, Lee H, et al. 2018; Clinicomanometric factors associated with clinically relevant esophagogastric junction outflow obstruction from the Sandhill high-resolution manometry system. Neurogastroenterol Motil. 30:e13221. DOI: 10.1111/nmo.13221. PMID: 29024314.

42. Schupack D, Katzka DA, Geno DM, Ravi K. 2017; The clinical significance of esophagogastric junction outflow obstruction and hypercontractile esophagus in high resolution esophageal manometry. Neurogastroenterol Motil. 29:1–9. DOI: 10.1111/nmo.13105. PMID: 28544670.

43. van Hoeij FB, Smout AJ, Bredenoord AJ. 2015; Characterization of idiopathic esophagogastric junction outflow obstruction. Neurogastroenterol Motil. 27:1310–1316. DOI: 10.1111/nmo.12625. PMID: 26095469.

44. Song BG, Min YW, Lee H, et al. 2019; Combined multichannel intraluminal impedance and high-resolution manometry improves detection of clinically relevant esophagogastric junction outflow obstruction. J Neurogastroenterol Motil. 25:75–81. DOI: 10.5056/jnm18148. PMID: 30646478. PMCID: PMC6326198.

45. Egan JV, Baron TH, et al. Standards of Practice Committee. 2006; Esophageal dilation. Gastrointest Endosc. 63:755–760. DOI: 10.1016/j.gie.2006.02.031. PMID: 16650533.

46. Siddiqui UD, Banerjee S, et al. ASGE Technology Committee. 2013; Tools for endoscopic stricture dilation. Gastrointest Endosc. 78:391–404. DOI: 10.1016/j.gie.2013.04.170. PMID: 23948186.

47. Sami SS, Haboubi HN, Ang Y, et al. 2018; UK guidelines on oesophageal dilatation in clinical practice. Gut. 67:1000–1023. DOI: 10.1136/gutjnl-2017-315414. PMID: 29478034. PMCID: PMC5969363.

48. de Wijkerslooth LR, Vleggaar FP, Siersema PD. 2011; Endoscopic management of difficult or recurrent esophageal strictures. Am J Gastroenterol. 106:2080–2092. DOI: 10.1038/ajg.2011.348. PMID: 22008891.

49. Kochman ML, McClave SA, Boyce HW. 2005; The refractory and the recurrent esophageal stricture: a definition. Gastrointest Endosc. 62:474–475. DOI: 10.1016/j.gie.2005.04.050. PMID: 16111985.

50. Repici A, Small AJ, Mendelson A, et al. 2016; Natural history and management of refractory benign esophageal strictures. Gastrointest Endosc. 84:222–228. DOI: 10.1016/j.gie.2016.01.053. PMID: 26828759.

51. Ramage JI Jr, Rumalla A, Baron TH, et al. 2005; A prospective, randomized, double-blind, placebo-controlled trial of endoscopic steroid injection therapy for recalcitrant esophageal peptic strictures. Am J Gastroenterol. 100:2419–2425. DOI: 10.1111/j.1572-0241.2005.00331.x. PMID: 16279894.

52. Hirdes MM, van Hooft JE, Koornstra JJ, et al. 2013; Endoscopic corticosteroid injections do not reduce dysphagia after endoscopic dilation therapy in patients with benign esophagogastric anastomotic strictures. Clin Gastroenterol Hepatol. 11:795–801.e1. DOI: 10.1016/j.cgh.2013.01.016. PMID: 23376318.

53. Spaander MC, Baron TH, Siersema PD, et al. 2016; Esophageal stenting for benign and malignant disease: European Society of Gastrointestinal Endoscopy (ESGE) clinical guideline. Endoscopy. 48:939–948. DOI: 10.1055/s-0042-114210. PMID: 27626318.

54. Fuccio L, Hassan C, Frazzoni L, Miglio R, Repici A. 2016; Clinical outcomes following stent placement in refractory benign esophageal stricture: a systematic review and meta-analysis. Endoscopy. 48:141–148. DOI: 10.1055/s-0034-1393331. PMID: 26528754.

55. Repici A, Hassan C, Sharma P, Conio M, Siersema P. 2010; Systematic review: the role of self-expanding plastic stents for benign oesophageal strictures. Aliment Pharmacol Ther. 31:1268–1275. DOI: 10.1111/j.1365-2036.2010.04301.x. PMID: 20236257.

56. Lu Q, Yan H, Wang Y, et al. 2019; The role of endoscopic dilation and stents in refractory benign esophageal strictures: a retrospective analysis. BMC Gastroenterol. 19:95. DOI: 10.1186/s12876-019-1006-0. PMID: 31221085. PMCID: PMC6585047.

57. Vakil N, Morris AI, Marcon N, et al. 2001; A prospective, randomized, controlled trial of covered expandable metal stents in the palliation of malignant esophageal obstruction at the gastroesophageal junction. Am J Gastroenterol. 96:1791–1796. DOI: 10.1111/j.1572-0241.2001.03923.x. PMID: 11419831.

58. Nagaraja V, Cox MR, Eslick GD. 2014; Safety and efficacy of esophageal stents preceding or during neoadjuvant chemotherapy for esophageal cancer: a systematic review and meta-analysis. J Gastrointest Oncol. 5:119–126. DOI: 10.3978/j.issn.2078-6891.2014.007. PMID: 24772340. PMCID: PMC3999625.

59. Shenfine J, McNamee P, Steen N, Bond J, Griffin SM. 2009; A randomized controlled clinical trial of palliative therapies for patients with inoperable esophageal cancer. Am J Gastroenterol. 104:1674–1685. DOI: 10.1038/ajg.2009.155. PMID: 19436289.

60. Hoyo C, Cook MB, Kamangar F, et al. 2012; Body mass index in relation to oesophageal and oesophagogastric junction adenocarcinomas: a pooled analysis from the International BEACON Consortium. Int J Epidemiol. 41:1706–1718. DOI: 10.1093/ije/dys176. PMID: 23148106. PMCID: PMC3535758.

61. Min YW, Jang EY, Jung JH, et al. 2017; Comparison between gastrostomy feeding and self-expandable metal stent insertion for patients with esophageal cancer and dysphagia. PLoS One. 12:e0179522. DOI: 10.1371/journal.pone.0179522. PMID: 28632744. PMCID: PMC5478133.

62. Song JH, Ko J, Min YW, et al. 2020; Comparison between percutaneous gastrostomy and self-expandable metal stent insertion for the treatment of malignant esophageal obstruction, after propensity score matching. Nutrients. 12:2756. DOI: 10.3390/nu12092756. PMID: 32927691. PMCID: PMC7551452.

63. Kim J, Min YW, Lee H, et al. 2018; Comparative study of esophageal self-expandable metallic stent insertion and gastrostomy feeding for dysphagia caused by lung cancer. Korean J Gastroenterol. 71:124–131. DOI: 10.4166/kjg.2018.71.3.124. PMID: 29566473.

64. Yu FJ, Shih HY, Wu CY, et al. 2018; Enteral nutrition and quality of life in patients undergoing chemoradiotherapy for esophageal carcinoma: a comparison of nasogastric tube, esophageal stent, and ostomy tube feeding. Gastrointest Endosc. 88:21–31.e4. DOI: 10.1016/j.gie.2017.11.030. PMID: 29225081.